Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Atea, Bridge, H. Lundbeck, Hipra Human Health, Invivyd, Moderna, Otsuka, Senhwa, Takeda.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: I-Mab, Sable, Shanghai Liuqiang Medical, Tracon.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Belief Biomed, Bionomics, Daewoong, I-Mab, Inmagene, Junshi, Lianbio, Olix, Otsuka, Ovid, SAB, Sunovion, Takeda.

Biopharmas in Asia-Pacific raising money in public or private financings: Adcentrx, Albatroz, Biomica, Mesoblast, Mezzion.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aquavit, Arcutis, Ascendis, Atsena, Biomea, BMS, Cabaletta, Erasca, Kiromic, Medincell, Neurosense, Onquality, Sanofi, Teva.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alloy, Blackhawk, CBMG, Destiny, Eterna, Exacis, IMV, J&J, Janssen, Lantern, Lundbeck, Medigene, Mindbio, Piramal, Plus, Science 37, Sporegen, Tay, Urogen, Vir, Vyne.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Almirall, CG, Eli Lilly, Horizon, J&J, Lipella, Pliant, Urogen, Zambon.

Biopharmas raising money in public or private financings, including: Adma, Anavo, Cyclo, Odimma, Ten63.

New hires and promotions in the biopharma industry, including: Amphista, Curve, Day One, Find, Glycoera, Newron, Obseva, Oramed, Resolution, Syneos, Tris.

The top 10 med-tech stock gainers and losers for the week.